|
Variable
|
Navoximod 21/28 days BID
|
Navoximod 28/28 days BID
|
All patients (n = 22)
|
|---|
| |
50 mg (n = 1)
|
100 mg (n = 3)
|
200 mg (n = 3)
|
400 mg (n = 3)
|
600 mg (n = 3)
|
800 mg (n = 6)
|
600 mg (n = 3)
| |
|---|
|
Age (yr), median (range)
|
65 (65-65)
|
58 (50-82)
|
63 (32-75)
|
54 (41-69)
|
58 (27-59)
|
69 (38-70)
|
67 (43-72)
|
61 (27-82)
|
|
Sex
|
|
Female
|
1 (100%)
|
–
|
3 (100%)
|
3 (100%)
|
3 (100%)
|
3 (50%)
|
2 (67%)
|
15 (68%)
|
|
Male
|
–
|
3 (100%)
|
–
|
–
|
–
|
3 (50%)
|
1 (33%)
|
7 (32%)
|
|
ECOG performance status
|
|
0
|
1 (100%)
|
1 (33%)
|
3 (100%)
|
–
|
1 (33%)
|
1 (17%)
|
2 (67%)
|
9 (41%)
|
|
1
|
–
|
2 (67%)
|
–
|
3 (100%)
|
2 (67%)
|
5 (83%)
|
1 (33%)
|
13 (59%)
|
|
Most common tumor types
|
|
Colorectal
|
–
|
–
|
–
|
2 (67%)
|
–
|
4 (67%)
|
–
|
6 (27%)
|
|
Head and neck
|
–
|
–
|
1 (33%)
|
1 (33%)
|
–
|
1 (17%)
|
–
|
3 (14%)
|
|
Leiomyosarcoma
|
–
|
1 (33%)
| |
–
|
–
|
–
|
1 (33%)
|
2 (9%)
|
|
Lung
|
–
|
1 (33%)
|
1 (33%)
|
–
|
–
|
–
|
–
|
2 (9%)
|
|
Pancreas
|
–
|
–
|
1 (33%)
|
–
|
1 (33%)
|
–
|
–
|
2 (9%)
|
|
Renal
|
–
|
–
|
–
|
–
|
1 (33%)
|
1 (17%)
|
–
|
2 (9%)
|
|
Bladder
|
1 (100%)
|
–
|
–
|
–
|
–
|
–
|
–
|
1 (5%)
|
|
Breast
|
–
|
–
|
–
|
–
|
–
|
–
|
1 (33%)
|
1 (5%)
|
|
Cholangiocarcinoma
|
–
|
1 (33%)
|
–
|
–
|
–
|
–
|
–
|
1 (5%)
|
|
Mesothelioma
|
–
|
–
|
–
|
–
|
–
|
–
|
1 (33%)
|
1 (5%)
|
|
Testicular
|
–
|
–
|
–
|
–
|
1 (33%)
|
–
|
–
|
1 (5%)
|
|
Number of prior systemic therapies, median (range)a
|
5 (5-5)
|
4 (1-5)
|
3 (1-3)
|
4 (3-4)
|
3 (2-9)
|
3.5 (2-6)
| | |
- ECOG Eastern Cooperative Oncology Group
- aAll patients underwent prior systemic therapy
